Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) have earned a consensus recommendation of "Moderate Buy" from the twenty-three analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $766.81.

A number of equities research analysts have issued reports on the stock. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $735.00 to $800.00 and gave the stock an "overweight" rating in a research note on Monday, September 12th. Jefferies Financial Group upgraded shares of Regeneron Pharmaceuticals from an "underperform" rating to a "hold" rating and increased their price objective for the stock from $536.00 to $675.00 in a research note on Thursday, September 8th. SVB Leerink raised their price target on shares of Regeneron Pharmaceuticals from $756.00 to $770.00 and gave the company a "market perform" rating in a research note on Friday, November 4th. Canaccord Genuity Group raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company a "buy" rating in a research note on Friday, September 16th. Finally, StockNews.com started coverage on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 12th. They issued a "hold" rating on the stock.

Regeneron Pharmaceuticals Trading Down 0.9 %

Shares of Regeneron Pharmaceuticals stock opened at $726.74 on Friday. The company has a market capitalization of $79.14 billion, a price-to-earnings ratio of 15.32, a PEG ratio of 2.14 and a beta of 0.21. The company has a quick ratio of 4.52, a current ratio of 5.36 and a debt-to-equity ratio of 0.13. Regeneron Pharmaceuticals has a 12-month low of $538.01 and a 12-month high of $779.00. The firm's 50-day moving average price is $739.88 and its two-hundred day moving average price is $669.39.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 264 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, December 12th. The shares were sold at an average price of $730.17, for a total value of $192,764.88. Following the completion of the sale, the executive vice president now owns 19,106 shares in the company, valued at approximately $13,950,628.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Marc Tessier-Lavigne sold 3,428 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, September 30th. The shares were sold at an average price of $698.00, for a total value of $2,392,744.00. Following the completion of the sale, the director now owns 2,269 shares in the company, valued at approximately $1,583,762. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 264 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, December 12th. The shares were sold at an average price of $730.17, for a total transaction of $192,764.88. Following the completion of the sale, the executive vice president now owns 19,106 shares of the company's stock, valued at approximately $13,950,628.02. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,142 shares of company stock worth $19,789,156. 8.99% of the stock is currently owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. FMR LLC grew its position in Regeneron Pharmaceuticals by 1.9% in the 2nd quarter. FMR LLC now owns 10,176,199 shares of the biopharmaceutical company's stock valued at $6,015,457,000 after purchasing an additional 193,175 shares during the period. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 8,648,125 shares of the biopharmaceutical company's stock worth $5,957,433,000 after acquiring an additional 77,380 shares during the last quarter. Capital World Investors boosted its holdings in Regeneron Pharmaceuticals by 11.8% during the 1st quarter. Capital World Investors now owns 5,949,834 shares of the biopharmaceutical company's stock worth $4,155,451,000 after acquiring an additional 626,199 shares during the last quarter. State Street Corp boosted its holdings in Regeneron Pharmaceuticals by 6.8% during the 1st quarter. State Street Corp now owns 5,125,467 shares of the biopharmaceutical company's stock worth $3,579,729,000 after acquiring an additional 325,645 shares during the last quarter. Finally, Dodge & Cox boosted its holdings in Regeneron Pharmaceuticals by 1.3% during the 2nd quarter. Dodge & Cox now owns 2,265,334 shares of the biopharmaceutical company's stock worth $1,339,107,000 after acquiring an additional 28,271 shares during the last quarter. Institutional investors and hedge funds own 84.25% of the company's stock.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Stories

• Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
• MarketBeat: Week in Review 12/19 – 12/23
• These Steelmakers Deserve A Place On Your 2023 Watch List
• Inflation Cools, Where Does The S&P 500 Go Now
• Cintas Beats Inflation With Operating Leverage
• Your Decision to Buy Palantir May Simply Be a Matter of Time

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.